No Sperm in Your Semen Analysis: What Happens Next

What the result means, and what it does not

Azoospermia means no sperm were found in a semen sample. It is a finding, not a diagnosis, and the first thing worth knowing is that it does not mean no sperm exist. The HFEA puts it simply: the amount you ejaculate is not linked to the amount of sperm in your semen, and sperm can often be collected surgically when they are absent from the ejaculate.

The second thing worth knowing is that a single result is not the end of testing. NICE recommends that where the first semen analysis is abnormal, a repeat should be offered — ideally at three months, to allow a full cycle of sperm formation — unless azoospermia or severe oligozoospermia is found, in which case the repeat should be as soon as possible. So a result of no sperm accelerates the process rather than closing it.

Two kinds, and the distinction drives everything

Obstructive azoospermia

Sperm are being made normally but cannot get out because something is blocking the route. NICE Clinical Knowledge Summaries list congenital causes such as congenital bilateral absence of the vas deferens and prostatic cysts, and acquired causes including epididymal or prostatic infection, vasectomy, and complications of surgery such as inguinal hernia repair or an operation for undescended testicles. Congenital absence of the vas deferens is frequently related to a mutation in the cystic fibrosis transmembrane regulator gene. Obstructive azoospermia accounts for 20–40% of men with azoospermia.

Non-obstructive azoospermia

Sperm production itself is impaired. Primary testicular failure is the most common cause, and NICE Clinical Knowledge Summaries list contributors including undescended testicles, testicular torsion or trauma, orchitis, chromosome disorders such as Y chromosome deletions and Klinefelter syndrome, systemic disease, radiotherapy and chemotherapy. In most cases — around 66% — the cause is not identified.

The tests that separate them

Expect an examination, blood tests including hormone measurement, and genetic testing. Hormone results help distinguish a production problem from a blockage. Genetic tests matter for two reasons: they can explain the finding, and they change what is recommended next.

NICE gives one recommendation here that is unusually definite: do not offer surgical sperm retrieval in the presence of Y chromosome AZFa or AZFb microdeletion. If those deletions are present, retrieval is not expected to succeed, and knowing that before an operation is worth a great deal.

Cystic fibrosis carrier testing is relevant where congenital absence of the vas deferens is suspected, because it has implications for any child as well as for the diagnosis.

What NICE recommends for each

Obstructive

NICE recommends offering either surgical correction or surgical sperm retrieval, deciding between them by taking into account the female partner's fertility factors such as age, ovarian reserve, tubal patency and ovulatory status, the obstructive interval if known, the risks and benefits of surgery, and personal preference. Surgical correction, where it works, can allow natural conception; retrieval requires ICSI.

Non-obstructive

NICE recommends offering surgical sperm retrieval, and when carrying it out, considering microscopic testicular sperm extraction — micro-TESE. The HFEA notes that many experts believe micro-TESE has the best chance of recovering sperm in non-obstructive azoospermia. It involves examining the testicle with an operating microscope to find tubules where sperm are being made, and is done under general anaesthetic.

The HFEA describes the other techniques used, mainly for obstruction: PESA and TESA use a fine syringe under local anaesthetic; TESE takes a small biopsy under local or general anaesthetic; MESA examines the epididymis under an operating microscope under general anaesthetic.

What retrieval does and does not guarantee

The HFEA is careful about this, and it is the single most important expectation to set. Successfully extracting sperm does not guarantee you will have a child. Retrieved sperm must be used in treatment, usually ICSI, and the chance of a baby then depends on that treatment and on sperm quality. There is no evidence that surgically collected sperm affects the chance of pregnancy or poses a risk to children conceived, though research suggests such sperm may not fertilise as well, possibly because some are of lower quality.

Practical point: if the sperm retrieved are of poor quality, your clinic may recommend using them immediately rather than freezing, because poor quality sperm are less likely to survive freezing. That can mean coordinating the retrieval with an egg collection.

Treatments that are not recommended

NICE is direct about several things sold into this space. Do not offer androgens to treat semen abnormalities. Only consider gonadotrophin or anti-oestrogen therapy for impaired semen parameters without hypogonadotropic hypogonadism as part of a clinical trial. Do not offer supplements, antioxidants or medical treatments to improve sperm DNA integrity. Do not offer antibiotics for leukocytes in semen unless there is an identified infection. The exception is genuine hypogonadotropic hypogonadism, where NICE recommends offering gonadotrophin therapy.

The HFEA's position on supplements is consistent: there is some evidence that certain antioxidants and vitamins may help men with low count or poor motility, but more research is needed before they can be called proven — and none of that applies to azoospermia, where the issue is not sperm quality but sperm absence.

If retrieval is not possible or does not work

NICE considers donor insemination effective for both obstructive and non-obstructive azoospermia, and for severe deficits in semen quality where a couple does not wish to have ICSI. Where donor sperm is used, NICE recommends confirming ovulation before treatment, offering tubal assessment if the history suggests tubal damage, and offering donor sperm IUI in preference to intracervical insemination because it improves pregnancy rates.

Two things are worth saying plainly. This diagnosis is common enough to have a standard pathway and rare enough that most people have never heard of it, which is a lonely combination. And male factor problems are involved in around 30% of couples seen for fertility problems — this is an ordinary finding in a fertility clinic, whatever it feels like when you read the report.